Flamen P - Search Results

1

Combining ¹⁸F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer.

Woff E, Kehagias P, Vandeputte C, Ameye L, Guiot T, Paesmans M, Hendlisz A, Flamen P. Woff E, et al. Among authors: flamen p. J Nucl Med. 2019 Oct;60(10):1366-1372. doi: 10.2967/jnumed.118.222919. Epub 2019 Mar 8. J Nucl Med. 2019. PMID: 30850494 Free article. Clinical Trial.

2

Positron emission tomography in colorectal cancer.

Flamen P. Flamen P. Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):237-51. doi: 10.1053/bega.2001.0283. Best Pract Res Clin Gastroenterol. 2002. PMID: 11969236 Review.

3

Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.

Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, Bormans G, Mortelmans L. Van Laere K, et al. Among authors: flamen p. Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):39-51. doi: 10.1007/s00259-004-1564-3. Epub 2004 Aug 10. Eur J Nucl Med Mol Imaging. 2005. PMID: 15309329

4

18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancer.

Muylle K, Castaigne C, Flamen P. Muylle K, et al. Among authors: flamen p. Curr Opin Oncol. 2005 May;17(3):249-53. doi: 10.1097/01.cco.0000160276.78762.17. Curr Opin Oncol. 2005. PMID: 15818169 Review.

5

18FDG PET in oncology: the best and the worst (Review).

Belhocine T, Spaepen K, Dusart M, Castaigne C, Muylle K, Bourgeois P, Bourgeois D, Dierickx L, Flamen P. Belhocine T, et al. Among authors: flamen p. Int J Oncol. 2006 May;28(5):1249-61. Int J Oncol. 2006. PMID: 16596242 Review.

6

Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma.

Belhocine T, Pierard GE, Frühling J, Letesson G, Bolle S, Hustinx R, Dargent JL, Flamen P, Rigo P. Belhocine T, et al. Among authors: flamen p. Oncol Rep. 2006 Aug;16(2):347-52. Oncol Rep. 2006. PMID: 16820914

7

Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres.

Van den Eynde M, Flamen P, El Nakadi I, Liberale G, Delatte P, Larsimont D, Hendlisz A. Van den Eynde M, et al. Among authors: flamen p. Clin Nucl Med. 2008 Oct;33(10):697-9. doi: 10.1097/RLU.0b013e318184b9a0. Clin Nucl Med. 2008. PMID: 18806572 No abstract available.

8

Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.

Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, Hendlisz A. Flamen P, et al. Phys Med Biol. 2008 Nov 21;53(22):6591-603. doi: 10.1088/0031-9155/53/22/019. Epub 2008 Oct 31. Phys Med Biol. 2008. PMID: 18978442

9

Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET.

Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P. Huyge V, et al. Among authors: flamen p. Clin Nucl Med. 2009 Jul;34(7):417-20. doi: 10.1097/RLU.0b013e3181a7d03c. Clin Nucl Med. 2009. PMID: 19542943

10

State of the art: radiolabeled microspheres treatment for liver malignancies.

Deleporte A, Flamen P, Hendlisz A. Deleporte A, et al. Among authors: flamen p. Expert Opin Pharmacother. 2010 Mar;11(4):579-86. doi: 10.1517/14656560903520916. Expert Opin Pharmacother. 2010. PMID: 20163269 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

178 results

Search Page

Filters